Drug Trial Radar · NCT01285700
Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
Last checked: Nov 20, 2026Latest source record: Sep 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
10
Actual
Start
Jan 2011
Primary completion
Jan 2012
Study completion Nov 2012
Sponsor
- Lead sponsor
- Zymenex A/SIndustry
- Sponsor type
- Industry
- Collaborators
- European Commission
- First posted
- Jan 28, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center, open-label, multiple-dose study of the efficacy and long-term safety of Lamazym for the treatment of patients with alpha-mannosidosis.
Conditions
- Alpha Mannosidosis
Interventions
LamazymDrug
ERT, infusion weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of Oligosaccharides in urineTime frame: 3 months (interim evaluation) + 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.